Hiroaki Matsumoto

Has grant

Associate professor

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Hiroaki Matsumoto is an Associate Professor at Yamaguchi University Hospital, Japan. His research areas encompass metastatic hormone-sensitive prostate cancer, urothelial carcinoma, and innovative treatment strategies, as highlighted in his recent articles focusing on risk stratification models and treatment efficacy. He actively contributes to clinical studies that refine treatment protocols and prognostic assessments within urology.

Recent Grants

Grant: Close

Development of novel markers for drug screening and descovery of mechanism to neuroendocrine differentiation in castration resistant prostate cancer

Open Date: 2016-04-01

Close Date: 2019-03-31

Grant: Close

The development of new therapeutic strategies through AMPK-mTOR pathway in renal cell carcinoma

Open Date: 2013-04-01

Close Date: 2016-03-31

Articles (11)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (1)

Keita Kobayashi

Yamaguchi University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hiroaki Matsumoto

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (11)

Refining the CHAARTED Classification: Clinical Utility of a Novel Integrated Risk Stratification Model Incorporating Gleason Grade and Biochemical Markers in Japanese Patients With Metastatic Hormone‐Sensitive Prostate Cancer

Prognostic risk score and index including the platelet-to-lymphocyte ratio and lactate dehydrogenase in patients with metastatic or unresectable urothelial carcinoma treated with immune checkpoint inhibitors

GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG‐1401

Editorial Comment to Significance of second progression‐free survival in patients with advanced urothelial cancer who received platinum‐based combination chemotherapy followed by pembrolizumab

Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non‐muscle invasive bladder cancer: A multi‐institutional collaborative study

The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study

Efficacy of combined androgen blockade therapy in patients with metastatic hormone‐sensitive prostate cancer stratified by tumor burden

Mucin‐producing urothelial‐type adenocarcinoma of the prostate diagnosed after robot‐assisted radical prostatectomy

Endoscopic laser treatment for urine leakage caused by an isolated calyx after robot‐assisted partial nephrectomy

Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study

Anti‐tumor efficacy of human anti‐c‐met CAR‐T cells against papillary renal cell carcinoma in an orthotopic model

Collaborators (1)

Keita Kobayashi

Make your next move.